All Updates

All Updates

icon
Filter
Partnerships
Compass Pathways partners with Hackensack Meridian Health partner for research on psilocybin treatment
Psychedelic Medicine
Jan 16, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jan 16, 2024

Compass Pathways partners with Hackensack Meridian Health partner for research on psilocybin treatment

Partnerships

  • Compass Pathways, a UK-based psychedelic company, has partnered with New Jersey-based healthcare network Hackensack Meridian Health to further research on the use of psilocybin in mental health treatments.

  • This collaboration will leverage Hackensack Meridian Health’s well-established expertise in mental health to better design the usage and delivery model of COMP360, Compass’ investigational psilocybin treatment for mental health issues.

  • Compass plans to extend the application of psilocybin beyond treating PTSD to other conditions, such as treatment-resistant depression and anorexia nervosa. Results from current research studies are expected to be released between summer 2024 and mid-2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.